SB
PFE icon

Strategic Blueprint’s Pfizer PFE Stock Holding History

Strategic Blueprint’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$741K Sell
30,778
-2,407
-7% -$63K 0.04% 363
2026
Q1 		$932K Sell
33,185
-128
-0.4% -$3.41K 0.05% 291
2025
Q4 		$829K Sell
33,313
-3,426
-9% -$86.4K 0.05% 304
2025
Q3 		$936K Sell
36,739
-2,091
-5% -$51.6K 0.04% 347
2025
Q2 		$941K Sell
38,830
-6,169
-14% -$144K 0.05% 307
2025
Q1 		$1.14M Sell
44,999
-2,170
-5% -$56.8K 0.06% 262
2024
Q4 		$1.25M Buy
47,169
+942
+2% +$25.6K 0.07% 225
2024
Q3 		$1.34M Sell
46,227
-6,162
-12% -$180K 0.08% 205
2024
Q2 		$1.47M Buy
52,389
+1,715
+3% +$47.2K 0.1% 184
2024
Q1 		$1.41M Buy
50,674
+14,865
+42% +$412K 0.1% 189
2023
Q4 		$1.03M Sell
35,809
-9,556
-21% -$289K 0.09% 221
2023
Q3 		$1.5M Buy
45,365
+1,043
+2% +$36.9K 0.14% 151
2023
Q2 		$1.63M Buy
44,322
+1,715
+4% +$66.8K 0.15% 136
2023
Q1 		$1.74M Sell
42,607
-45,042
-51% -$1.95M 0.18% 130
2022
Q4 		$4.49M Buy
87,649
+50,855
+138% +$2.44M 0.52% 40
2022
Q3 		$1.61M Buy
36,794
+2,488
+7% +$121K 0.19% 126
2022
Q2 		$1.8M Buy
34,306
+1,718
+5% +$87.5K 0.22% 113
2022
Q1 		$1.69M Buy
32,588
+1,685
+5% +$87.4K 0.2% 111
2021
Q4 		$1.82M Buy
30,903
+2,803
+10% +$139K 0.23% 96
2021
Q3 		$1.21M Buy
28,100
+1,235
+5% +$54.7K 0.19% 117
2021
Q2 		$1.05M Buy
26,865
+1,776
+7% +$69.1K 0.16% 127
2021
Q1 		$909K Buy
25,089
+828
+3% +$29.4K 0.19% 112
2020
Q4 		$893K Buy
24,261
+4,643
+24% +$170K 0.22% 97
2020
Q3 		$683K Buy
19,618
+8,521
+77% +$299K 0.21% 94
2020
Q2 		$344K Buy
11,097
+133
+1% +$4.52K 0.12% 115
2020
Q1 		$340K Buy
10,964
+13
+0.1% +$443 0.2% 81
2019
Q4 		$407K Buy
10,951
+8,614
+369% +$307K 0.28% 57
2019
Q3 		$80K Sell
2,337
-36,647
-94% -$1.33M 0.06% 122
2019
Q2 		$1.6M Buy
38,984
+2,385
+7% +$94.7K 1.37% 29
2019
Q1 		$1.48M Buy
36,599
+3,300
+10% +$132K 1.34% 27
2018
Q4 		$1.38M Buy
+33,299
New +$1.38M 2% 20

Other funds holding PFE

Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
SLAM
Swiss Life Asset Management Zurich $24.1B AUM 38.82% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Strategic Blueprint's PFE Position: Q2 2026 in Review

Strategic Blueprint reduced its Pfizer (PFE) stake by 7.3% in Q2 2026, selling an estimated $63K and leaving 30,778 shares worth $741K. The position accounts for 0.04% of the portfolio, ranked #363.

Strategic Blueprint first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $4.49M in Q4 2022. 1,334 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Strategic Blueprint held 30,778 shares of Pfizer worth $741K as of Q2 2026.
  • Strategic Blueprint sold 2,407 Pfizer shares in Q2 2026, an estimated $63K.
  • Pfizer made up 0.04% of Strategic Blueprint's portfolio in Q2 2026, its #363 holding.
  • Strategic Blueprint first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
  • Strategic Blueprint's Pfizer position peaked at $4.49M in Q4 2022.
  • 1,334 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Strategic Blueprint's 13F filing for Q2 2026, filed 23 Jul 2026.